Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434824
Status:
COMPLETED
Last Update Posted:
2015-04-16
First Post:
2007-02-12
Brief Title:
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism 43203
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Randomized Parallel-Group Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency
Status:
COMPLETED
Status Verified Date:
2015-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study we have evaluated the effects of three different doses of oral testosterone undecanoate in aging men presenting with a combination of symptoms suggestive of hypogonadism and low blood levels of the male hormone testosterone
Specifically we have studied the effects on
symptoms suggestive of low testosterone levels
blood testosterone and other hormone levels
bone mass
muscle mass and fat mass
muscle strength
prostate
lipids hematocrit
Specifically we have studied the effects on
symptoms suggestive of low testosterone levels
blood testosterone and other hormone levels
bone mass
muscle mass and fat mass
muscle strength
prostate
lipids hematocrit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None